Binder	Affinity IC50 (nM)	DLL3 domain	Cross-reactivity Cyno DLL3	Mouse DLL3	Human DLL1	Human DLL4
ML DLL3 Binder	3.6225	EGF6	+++	+	-	-

FIG. 1




FIG. 2A



Percent CAR positive
100
80
60
40
20
0
Untransduced
Comp 1
hrabmAb CAR 1
hrabmAb CAR 2
hrabmAb CAR 3
hrabmAb CAR 4
hrabmAb CAR 5
hrabmAb CAR 6
hrabmAb CAR 7
hrabmAb CAR 8
ML73
hrabmAb CAR 9

FIG. 2B



CAR MFI
30000
20000
10000
0
Untransduced
Comp 1
hrabmAb CAR 1
hrabmAb CAR 2
hrabmAb CAR 3
hrabmAb CAR 4
hrabmAb CAR 5
hrabmAb CAR 6
hrabmAb CAR 7
hrabmAb CAR 8
ML73
hrabmAb CAR 9

FIG. 2C



150000
100000
50000
0
IFN-γ (pg/mL)
Untransduced
Comp 1
hrabmAb CAR 1
hrabmAb CAR 2
hrabmAb CAR 3
hrabmAb CAR 4
hrabmAb CAR 5
hrabmAb CAR 6
hrabmAb CAR 7
hrabmAb CAR 8
ML73
hrabmAb CAR 9

FIG. 3A



15000
10000
5000
0
IL-2 (pg/mL)
Untransduced
Comp 1
hrabmAb CAR 1
hrabmAb CAR 2
hrabmAb CAR 3
hrabmAb CAR 4
hrabmAb CAR 5
hrabmAb CAR 6
hrabmAb CAR 7
hrabmAb CAR 8
ML73
hrabmAb CAR 9

FIG. 3B



Percent CAR positive
100
80
60
40
20
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 4A



CAR MFI
30000
20000
10000
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 4B



A549
IFN-γ (pg/mL)
6000
4000
2000
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 5A



A549
IL-2 (pg/mL)
25
20
15
10
5
0
Untransduced
Comp 2
Comp 3
Comp 5
ML73
Comp 4
Comp 1

FIG. 5B



DMS273
IL-2 (pg/mL)
800
600
400
200
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 6A



DMS273
IL-2 (pg/mL)
800
600
400
200
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 6B



SHP-77
IL-2 (pg/mL)
4000
3000
2000
1000
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 6C



DMS273
IFN-γ (pg/mL)
40000
30000
20000
10000
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 6D



DMS273
IFN-γ (pg/mL)
40000
30000
20000
10000
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 6E



DMS273
IFN-γ (pg/mL)
40000
30000
20000
10000
0
Untransduced
ML73
Comp 1
Comp 2
Comp 3
Comp 4
Comp 5

FIG. 6F



3000
2000
1000
0
Tumor volume (mm3)
Untransduced
T cell
injection
Comp 2
ML73
0
20
40
60
80
Days post tumor inoculation

FIG. 7A



100
50
0
Percent Survival
ML73
Untransduced
Comp 2
0
20
40
60
80
Days post tumor inoculation

FIG. 7B



100
80
60
40
20
0
CAR+ %
Untransduced
LVV.ML73
AAV.ML73

FIG. 8A



10000
8000
6000
4000
2000
0
CAR MFI
Untransduced
LVV.ML73
AAV.ML73

FIG. 8B



80000
60000
40000
20000
0
IFNγ pg/mL
UTD
ML73.LVV
ML73.AAV
A375
SHP-77
DMS-273

FIG. 8C



4000
3000
2000
1000
0
IL-2 pg/mL
UTD
LVV.ML73
AAV.ML73
A375
SHP-77
DMS-273

FIG. 8D




FIG. 9A

FIG. 9B

FIG. 9C